<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739946</url>
  </required_header>
  <id_info>
    <org_study_id>2012-143</org_study_id>
    <nct_id>NCT01739946</nct_id>
  </id_info>
  <brief_title>Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.</brief_title>
  <official_title>Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Chancellor, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to compare protein markers in the urine of patients with and
      without overactive bladder (OAB) and InterStim®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will look for changes in protein markers that might reflect bladder symptoms
      before and after InterStim® implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nerve Growth Factor (NGF) levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>pg/ml</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Implanted subject</arm_group_label>
    <description>Subjects with Interstim implanted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Subjects without Interstim implanted</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with either have OAB and will be undergoing an InterStim® implant (InterStim®
        group) or do not have bladder symptoms or an InterStim® device (Control group)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        OAB subjects (n=10 Phase I and n=10 Phase II)

        Inclusion Criteria:

          -  Female

          -  Age 18-75 years

          -  Clinical symptoms of OAB (urgency and frequency with or without urge incontinence) for
             at least 3 or the 6 months immediately before the first visit.

          -  At least 8 voids/day and an average of 1 nocturnal void over 3 consecutive days on
             baseline bladder diary.

          -  InterStim® treatment naïve or being revised with a new lead

        Exclusion Criteria:

          -  Pelvic mass, pelvic prolapse, urinary retention, and pelvic malignancies as revealed
             by physical examination/medical record review

          -  Implanted Programmable Generator (IPG) is not implanted/connected to the tined lead
             (failed Stage I)

          -  Revision of only the IPG (without replacement of the tined lead)

          -  More than one InterStim® device being placed (undergoing bilateral stimulation)

        Controls (n=10)

        Inclusion:

          -  Female

          -  Age 18-75 years

          -  Deny history of OAB diagnosis or symptoms (urgency and frequency with or without urge
             incontinence)

          -  American Urological Association (AUA) symptom score of ≤4

        Exclusion:

        -History of pelvic mass, prolapse, urinary retention, or pelvic malignancy within the last
        year
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Chancellor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Michael Chancellor, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

